(Note: Healthcare Royalty, Inc. postponed its IPO indefinitely “due to market conditions” on Friday morning, Aug. 6, 2021, the day that the IPO was initially expected to start trading on the NASDAQ.)

We are the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016. We focus on growth assets and emerging companies driving innovation in the biopharmaceutical industry. We consider “mid-market” to comprise royalty acquisitions for transaction sizes between $20 million and $250 million. Our founders have been pioneers in the healthcare royalty and debt financing markets since 2001, and formed HCR in 2006 to build on their leadership in collaborating with inventors, academic institutions, small and mid-cap biotechnology companies and leading global pharmaceutical companies. Our in-house scientific, regulatory and transactional capabilities differentiate us from other industry participants and are the basis for our reputation among potential partners as knowledgeable, creative and able to solve complex and potentially significant financing needs.

We have purposefully built a diverse portfolio across the therapeutic spectrum, including blockbuster assets such as Shingrix, innovative growth products such as Krystexxa, and recently launched products such as Xpovio.

*Note: Adjusted EBITDA was $436 million for the 12 months that ended March 31, 2021, according to financial statements in the prospectus.

*Note: Net investment income was $215.18 million for the 12 months that ended March 31, 2021, according to the prospectus.